MentionFox
Home › Executive changes › Aurinia Pharmaceuticals Inc.
Leadership changes · AUPH · SEC Form 8-K, Item 5.02

Leadership changes at Aurinia Pharmaceuticals Inc. (2026)

Before you join, sell to or invest in Aurinia Pharmaceuticals Inc.

MentionFox check on Aurinia Pharmaceuticals Inc.: no red flags found in 3 sources; 1 item to note (checked 14 November 2026). mentionfox.com/c/executive-changes/aurinia-pharmaceuticals

  • Note: Layoff plan disclosed Nov 2024 (filing)

New since last check: Layoff plan disclosed Nov 2024 (filing, first seen 14 November 2026).

Check Aurinia Pharmaceuticals Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Aurinia Pharmaceuticals Inc.?

Who joined and who left Aurinia Pharmaceuticals Inc. (AUPH)? 3 appointments reported on 2026-03-23, each cited to the company's own filing.

Kevin Tang was named Chief Executive Officer of Aurinia Pharmaceuticals Inc., effective March 23, 2026. As of November 14, 2026, Aurinia Pharmaceuticals Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 23, 2026, naming 3 appointments (Form 8-K, March 23, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies ↓

Sell to companies like Aurinia Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · In / out: In · Person: Kevin Tang · Role: Chief Executive Officer · Effective: 2026-03-23 · 8-K, 2026-03-23
  • · In / out: In · Person: Ryan Cole · Role: Chief Operating Officer · Effective: 2026-03-23 · 8-K, 2026-03-23
  • · In / out: In · Person: Michael Hearne · Role: Chief Financial Officer · Effective: 2026-03-23 · 8-K, 2026-03-23
Changes3
In (appointed)3
Latest filing2026-03-23

Aurinia Pharmaceuticals Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-23. It names 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Aurinia Pharmaceuticals Inc. files it.

Layoffs on record: 2 filings or notices, latest 2024-11-07 (layoff filings and notices).

Also on the record for Aurinia Pharmaceuticals Inc.

DateRecordFigureOur pageSource
August 26, 2026Stake report, Schedule 13D/A, by ILJIN SNT Co., Ltd.4.4% of the class5%+ stakesSource
June 4, 2026Stake report, Schedule 13D/A, by TANG CAPITAL MANAGEMENT, LLC10% of the class5%+ stakesSource
March 25, 2026Stake report, Schedule 13D/A, by TANG CAPITAL MANAGEMENT, LLC9.2% of the class5%+ stakesSource
March 3, 2026Stake report, Schedule 13D/A, by TANG CAPITAL MANAGEMENT, LLC9.2% of the class5%+ stakesSource
August 13, 2025Stake report, Schedule 13D/A, by ILJIN SNT Co., Ltd.5% of the class5%+ stakesSource

Selling to them or working with them? See who runs Aurinia Pharmaceuticals Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Aurinia Pharmaceuticals Inc. and the records around it.

Aurinia Pharmaceuticals Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Aurinia Pharmaceuticals Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Aurinia Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Aurinia Pharmaceuticals Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    7 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-23InChief Executive Officer2026-03-238-K, 2026-03-23
2026-03-23InChief Operating Officer2026-03-238-K, 2026-03-23
2026-03-23InChief Financial Officer2026-03-238-K, 2026-03-23

Who leads Aurinia Pharmaceuticals Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Aurinia Pharmaceuticals Inc.?

New leaders reset buying decisions — get the Full Report on Aurinia Pharmaceuticals Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Aurinia Pharmaceuticals Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Executive Officer at Aurinia Pharmaceuticals Inc., with the record behind each one.

Find candidates like Chief Executive Officer at Aurinia Pharmaceuticals Inc.

Every change, in the filing's words

Filed 2026-03-23 · 8-K

Appointed: Kevin Tang, Chief Executive Officer, effective 2026-03-23

Effective March 23, 2026, the Board of Directors of Aurinia Pharmaceuticals Inc. ("Aurinia") appointed Kevin Tang as Aurinia's Chief Executive Officer and as Aurinia's principal executive officer.

Appointed: Ryan Cole, Chief Operating Officer, effective 2026-03-23

Effective March 23, 2026, Aurinia's Board of Directors appointed Ryan Cole as Aurinia's Chief Operating Officer.

Appointed: Michael Hearne, Chief Financial Officer, effective 2026-03-23

Effective March 23, 2026, Aurinia's Board of Directors appointed Michael Hearne as Aurinia's Chief Financial Officer and as Aurinia's principal financial officer and principal accounting officer.

Also stated in this filing

  • Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
  • Mr. Tang, age 59, has served as Chair of Aurinia's Board of Directors since 2024.
  • He is President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002.
  • From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company.
  • In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022.
  • Mr. Tang co-founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020.
  • From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012.
  • From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group.
  • Mr. Tang received a B.S. degree from Duke University.

Tools for this story

Each opens in a new tab, filled in for Aurinia Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/aurinia-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Aurinia Pharmaceuticals Inc. names Kevin Tang CEO (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/aurinia-pharmaceuticals